Xvivo Perfusion AB (3XV) Financial Statements
Xvivo Perfusion AB Financial Overview
Xvivo Perfusion AB's market cap is currently $586.45M. The company's EPS TTM is $4.09; its P/E ratio is 50.12; Xvivo Perfusion AB is scheduled to report earnings on January 28, 2027, and the estimated EPS forecast is $0.08. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 812.16M | $ 822.41M | $ 597.54M | $ 415.29M | $ 258.39M |
| Gross Profit | $ 533.50M | $ 616.41M | $ 445.11M | $ 296.96M | $ 188.28M |
| Operating Income | $ 93.02M | $ 88.35M | $ 4.19M | $ 23.18M | $ 6.98M |
| EBITDA | $ 153.14M | $ 272.97M | $ 35.05M | $ 65.58M | $ 39.20M |
| Net Income | $ 25.16M | $ 172.18M | $ 91.82M | $ 18.43M | $ 8.15M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 292.09M | $ 415.52M | $ 546.09M | $ 246.54M | $ 398.70M |
| Total Assets | $ 2.37B | $ 2.40B | $ 2.20B | $ 1.73B | $ 1.54B |
| Total Debt | $ 124.72M | $ 34.04M | $ 31.44M | $ 10.01M | $ 5.72M |
| Net Debt | $ -167.37M | $ -381.48M | $ -514.35M | $ -236.54M | $ -392.98M |
| Total Liabilities | $ 260.65M | $ 245.97M | $ 250.57M | $ 302.95M | $ 257.15M |
| Stockholders' Equity | $ 2.11B | $ 2.16B | $ 1.95B | $ 1.43B | $ 1.29B |
| Cash Flow | |||||
| Free Cash Flow | $ -151.84M | $ -81.86M | $ -97.65M | $ -103.09M | $ -106.13M |
| Operating Cash Flow | $ 101.07M | $ 111.29M | $ 46.29M | $ 27.86M | $ -12.06M |
| Investing Cash Flow | $ -258.41M | $ -243.81M | $ -161.62M | $ -197.62M | $ -187.70M |
| Financing Cash Flow | $ 72.25M | $ -10.90M | $ 418.55M | $ -6.84M | $ 234.61M |
Currency in SEK